Engineering the future of 3D pathology.

"Conflict of interest statement: JTCL is a cofounder and board member of Alpenglow Biosciences, Inc., which has licensed the OTLS microscopy portfolio developed in his lab at the University of Washington. AJ reports personal fees from Roche, Merck, and personal fees from Lunaphore outside the submitted work. CV and RC are the Principal Investigators of Articulate Pro, a study evaluating Paige Prostate, which is funded by the UK Department of Health and Social Care direct to Oxford University. Oxford University and Oxford University Hospital NHS Foundation Trust are part of the PathLAKE AI Centre of Excellence which has received in‐kind industry investment from Philips. LDT is a cofounder of Alpenglow Biosciences, Inc."

"The authors acknowledge funding support from the Department of Defense (DoD) Prostate Cancer Research Program (PCRP) through W81WH‐18‐10358 (JTCL and LDT) and W81XWH‐20‐1‐0851 (JTCL). Support was also provided by the National Cancer Institute (NCI) through R01CA268207 (JTCL), U01CA239055 (AJ), U01CA248226 (AJ), and the Pacific Northwest Prostate Cancer SPORE – P50CA097186 (LDT). Additional support was provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) through R01EB031002 (JTCL), the National Institute of Digestive Diseases and Kidney (NIDDK) through U01DK133090 (AJ) and R01DK118431 (AJ), the National Library of Medicine (NLM) through R01LM013864 (AJ), the PCUK Charity (CV, RC, JTCL), the NSF through 1934292 HDR: I‐DIRSE‐FW (JTCL), the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (CV), UK Research and Innovation (RC), and the Canary Foundation (LDT)."